Pyxis Oncology
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is a novel extracellular ADC against a noncellular cancer target, EDB+FN. MICVO is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
